![]() ![]() To see all exchange delays and terms of use please see disclaimer. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. ![]() © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. provides comprehensive coverage of insider trading, including recent insider buying, recent insider selling, and education about insider trading. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. © American Consumer News, LLC dba ™ 2019-2023. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. It has collaboration agreements with HemoShear Therapeutics, LLC Alpine Immune Sciences, Inc. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use DUEXIS (ibuprofen/famotidine) tablets for oral use RAYOS (prednisone) delayed-release tablets for oral use and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion KRYSTEXXA (pegloticase injection) for intravenous infusion RAVICTI (glycerol phenylbutyrate) oral liquid PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use QUINSAIR (levofloxacin) solution for inhalation and UPLIZNA (inebilizumab-cdon) injection for intravenous use. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. ![]() Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Before BMO, he held investment banking roles at JMP Securities and Stout, where he provided advisory services, including for capital raising and M&A activities, to companies across a wide range of sectors.Ĭox earned a Master of Business Administration from the University of Chicago and a Bachelor of Business Administration in finance from the University of Notre Dame. Cox also previously spent time on Horizon’s business development team, where he supported multiple acquisitions, financings and licensing transactions.īefore joining Horizon, Cox was vice president, capital markets at BMO Capital Markets, where he advised clients on debt financing transactions across various levels of the capital structure. Aaron Cox joined Horizon in 2016 and has served in various roles across finance, business development and corporate development, including as executive vice president, finance chief of staff for the chairman, president and chief executive officer and senior vice president, corporate development, where he had responsibilities spanning financial planning, corporate strategy, mergers and acquisitions (M&A), acquisition integration, capital markets planning, real estate, security and investor relations. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |